Additionally, biologic DMARD therapies—although costly—may be cost-effective in childhood rheumatologic disease: tumor necrosis factor (TNF) inhibitors for the treatment of JIA and JIA-associated uveitis, for example, are potentially cost-effective from a health payer perspective [7, 8]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.